Is desmopressin FDA-approved, and what does the research show?

What is desmopressin?

Desmopressin is a man-made copy of vasopressin, the hormone the pituitary gland releases to make the kidneys hold on to water ¹, ⁷. Vasopressin is also called antidiuretic hormone, or ADH, because it cuts the amount of urine the body makes ⁷. Vasopressin itself is a separate prescription medicine, described on its own page. Desmopressin is vasopressin with its structure altered ¹. Those changes make the antidiuretic effect last longer and weaken the hormone's effects on blood vessels and on the smooth muscle of internal organs ¹.

It is a small synthetic peptide, and medicines contain it as desmopressin acetate ¹, ⁷. Beyond water balance, it raises the blood's level of factor VIII activity, a clotting protein, in people with hemophilia A and type 1 von Willebrand's disease, two bleeding disorders ¹. FDA approved it as DDAVP, and generic versions of the injection, the tablets and the nasal spray are approved today ².

Is desmopressin FDA-approved?

Yes, desmopressin acetate is FDA-approved and prescription-only in several forms, and has been since 1978 ¹, ². FDA's Drugs@FDA record shows the first approval, new drug application NDA 017922 for the DDAVP nasal solution, on February 21, 1978 ². FDA classed it as a new molecular entity, its term for a drug not approved before ². The DDAVP nasal spray products themselves are now listed as discontinued, with FDA's note that they were not withdrawn for safety or effectiveness reasons ². The nasal spray listed today is generic ², ⁶.

The DDAVP injection followed on March 30, 1984, and DDAVP tablets on September 6, 1995, and both carry marketing status "Prescription" ³, ⁴. The newest product, the Desmoda oral solution, was approved on February 25, 2026 for central diabetes insipidus in adults and children ⁵, ¹¹. Stimate, a higher-strength nasal spray approved in 1994, is listed as discontinued ¹².

The injection label approves it "as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus" ¹. It also covers the temporary excess urination and thirst that can follow head trauma or pituitary surgery ¹. Central diabetes insipidus is a shortage of the body's own antidiuretic hormone, and the label calls desmopressin "a replacement hormone for antidiuretic hormone" in that condition ¹.

The same label says it "is ineffective and not indicated for the treatment of nephrogenic diabetes insipidus," the kidney-origin form ¹. The injection is also approved in hemophilia A and in mild to moderate type 1 von Willebrand's disease, the two bleeding disorders ¹. The label limits those uses to patients whose factor VIII activity is above 5 percent ¹. There it is used "to maintain hemostasis during surgical procedures and postoperatively," that is, to stop bleeding, and to reduce bleeding in spontaneous or injury-related episodes, such as bleeding into joints, muscles or mucous membranes ¹.

The tablets add a third use, "the management of primary nocturnal enuresis," bedwetting in children, alone or alongside behavioral treatment ⁷. The nasal spray is approved for central diabetes insipidus in adults and children aged 4 and older ¹⁰. Its label states it is not indicated for bedwetting, because reports after the drug was on the market showed "a higher risk of hyponatremia and hyponatremic convulsions" with the nasal spray than with tablets ¹⁰.

Two products were approved for nocturia, the Noctiva nasal spray on March 3, 2017 and the Nocdurna tablet, taken under the tongue, on June 21, 2018 ⁸, ⁹. Their labels approve them "for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void" ¹³, ¹⁴. Nocturia is waking at night to urinate, and nocturnal polyuria means the night's urine exceeds one third of the whole day's, as the trials defined it ¹³. Drugs@FDA lists both products with marketing status "Discontinued" as of November 9, 2026 ⁸, ⁹.

No desmopressin label approves it for weight, muscle, performance or aging ¹, ¹⁰, ⁷, ¹³, ¹⁴, ¹¹. The route to it is a licensed clinician's prescription, after the blood sodium test the label requires before treatment starts ¹. The injection label cited here was issued June 2026, the nasal spray's is dated September 2018 and the tablets' July 2020 ¹, ¹⁰, ⁷.

See the FDA status of every peptide, updated weekly.

How does desmopressin work?

Desmopressin binds the vasopressin 2 receptor, called V2, on cells lining the kidney's collecting ducts, where urine is concentrated before it leaves the kidney ¹, ¹³, ¹¹. Switching that receptor on makes the cells draw water back into the blood ¹, ¹³. In central diabetes insipidus it stands in for the hormone the pituitary is not supplying ¹. The label says this reduces urine output, concentrates the urine and dilutes the blood ¹.

In hemophilia A and type 1 von Willebrand's disease it works differently, raising the blood's factor VIII activity ¹. The rise is "rapid and evident within 30 minutes," peaks at 90 minutes to two hours, and how long its effect on clotting lasts depends on factor VIII's half-life, about 8 to 12 hours ¹. Given too often, the response fades, which the label calls tachyphylaxis ¹. These are the label's accounts, for an approved drug ¹.

What does the research show?

The evidence is at the top tier, FDA approval, with the tablets' and the nocturia products' labels describing controlled trials ⁷, ¹³, ¹⁴. The nocturia products rest on placebo-controlled trials of a few hundred to a thousand people, placebo-controlled meaning tested against a dummy treatment ¹³, ¹⁴. The injection label gives no trial sizes for its uses, and its pharmacology section reports the factor VIII response instead ¹.

Studied in people with central diabetes insipidus: the tablet label describes four long-term studies of 46 patients treated for 12 to 44 months ⁷. It reports no loss of effect, no antibodies to the drug and no rise in blood pressure ⁷. The 2026 oral solution's label says its effectiveness "was supported by dose response studies of desmopressin acetate tablets" ¹¹.

Studied in children with bedwetting: two randomized, double-blind, placebo-controlled studies enrolled 340 patients aged 5 to 17, 72 percent of them boys, and evaluated 329 ⁷. Randomized means chance assigned each child to drug or placebo, and double-blind means neither families nor doctors knew which. Over a two-week baseline they averaged 10 wet nights per two weeks ⁷. After two weeks of treatment, wet nights fell by 1 on placebo, a 10 percent reduction ⁷.

They fell by 3, 3 and 4 across three rising dose levels, reductions of 27, 30 and 40 percent, each significant against placebo ⁷. In a six-month open-label extension, where everyone knowingly took the drug and in which 230 patients were evaluated, 56 percent had at least a 50 percent reduction in wet nights ⁷. Thirty-eight percent had a complete or near-complete response ⁷.

A Cochrane review, an independent pooled analysis of trials, published online July 29, 2025, covered 95 studies of 8,473 children, 5,434 of them on desmopressin ¹⁵. Against placebo, desmopressin "may reduce the mean number of wet nights per week," by 1.81 nights (95 percent confidence interval 1.39 to 2.24, the range the true figure likely sits in; 1,267 participants in 16 studies), low-certainty evidence ¹⁵. It "probably leads to more children achieving 14 consecutive dry nights" (risk ratio 3.18, about three times as likely, 95 percent confidence interval 1.75 to 5.80; 922 participants in 11 studies), moderate-certainty evidence ¹⁵.

Against bedwetting alarms, the review says "It is uncertain if there is any difference" in wet nights at the end of treatment, very low certainty ¹⁵. In children reaching 14 consecutive dry nights there "may be little or no difference," low certainty ¹⁵. Alarm therapy "may improve the number of children who are dry at follow-up," moderate certainty ¹⁵. Overall the authors assessed the quality of the evidence "as low or very low" ¹⁵.

Studied in adults with nocturia: the Nocdurna trials were two three-month randomized, double-blind, placebo-controlled trials, one of 237 women and one of 230 men ¹⁴. All had nocturnal polyuria and at least two nighttime voids ¹⁴. Women started at 2.9 voids a night on average ¹⁴. Their voids fell by 1.5 on Nocdurna and by 1.2 on placebo, a difference of 0.3 (95 percent confidence interval 0.1 to 0.5) ¹⁴.

Men started at 3.0, and their voids fell by 1.3 against 0.9, a difference of 0.4 (0.2 to 0.6) ¹⁴. Nights with at most one void were 58 percent on Nocdurna against 45 percent on placebo in women, and 44 against 32 percent in men ¹⁴.

The Noctiva trials were two 12-week randomized, double-blind, placebo-controlled trials in 1,045 adults aged 50 and older, mean age 67 ¹³. On the higher dose, nightly voids fell by 1.5 against 1.2 on placebo in the first trial ¹³. In the second they fell by 1.5 against 1.1, differences of 0.3 and 0.4 ¹³. At least a 50 percent reduction was reached by 47 and 49 percent on the higher dose against 27 and 29 percent on placebo ¹³. The lower dose "did not meet all prespecified efficacy endpoints," the label says ¹³.

A pooled analysis of the two trials was published online April 12, 2018 ¹⁶. It counted all 1,333 patients the trials randomized, while the label's 1,045 are those among them with nocturnal polyuria ¹⁶, ¹³. It reported hyponatremia, defined as sodium at or below 125, or below 130 with symptoms, in 1.1 percent on the higher dose against 0.2 percent on placebo ¹⁶.

A systematic review published online April 1, 2014 covered 10 trial reports in 2,191 adults with nocturia and found desmopressin "appears to offer a modest benefit" ¹⁷. One dose level gave just over an hour more sleep before the first void and 0.72 fewer voids a night than placebo, with no significant gain at higher doses ¹⁷. Hyponatremia and headache occurred at 5.1 and 4.3 times the placebo rate ¹⁷. Four of the ten first gave everyone the drug and dropped non-responders and those with side effects, a design the authors rated at high risk of bias ¹⁷.

What has not been studied: Noctiva "has not been studied in patients less than 50 years of age," and Nocdurna's safety and effectiveness "have not been established in pediatric patients" ¹³, ¹⁴. No trial of desmopressin for weight, body composition, athletic performance or aging was found among this page's sources as of November 10, 2026 ¹, ¹⁰, ⁷, ¹³, ¹⁴, ¹¹, ¹⁶, ¹⁵, ¹⁷.

What are the side effects?

Low blood sodium leads, and FDA put it in a boxed warning. The injection label opens with it: "Desmopressin acetate can cause hyponatremia. Severe hyponatremia can be life-threatening, leading to seizures, coma, respiratory arrest, or death" ¹. The Noctiva and Nocdurna labels carry the same boxed warning in their own names ¹³, ¹⁴. Hyponatremia is low sodium in the blood, and here it comes from the body holding water it would otherwise pass as urine ¹⁰.

The boxed warning requires a normal blood (serum) sodium before starting, then a measurement within 7 days and at about one month ¹. It calls for more frequent checks in people 65 and older ¹. The tablet, nasal spray and oral solution labels carry the same hazard under Warnings: "Unless properly diagnosed and treated hyponatremia can be fatal" ¹⁰, ⁷, ¹¹. The signs the labels list are headache, nausea or vomiting, weight gain, restlessness, fatigue, lethargy, disorientation, loss of appetite, irritability, muscle weakness or cramps and confusion ¹⁰, ¹¹. In severe cases they are seizure, coma or respiratory arrest ¹⁰.

The trials measured how often sodium fell. A pooled analysis of three Nocdurna studies counted sodium just below the normal range, 130 to 134 mmol/L ¹⁴. It occurred in 7 percent of women on Nocdurna against 4 percent on placebo ¹⁴.

In men it was 17 percent against 3 percent ¹⁴. Among men aged 65 and older it was 23 percent against under 1 percent, and three men on Nocdurna, 2 percent, fell to 125 or below ¹⁴. The label set women a lower dose because in the trials they were more sensitive and had more hyponatremia at the dose given to men ¹⁴.

In the Noctiva trials, sodium of 130 to 134 occurred in 12.3 percent on the higher dose against 5.2 percent on placebo ¹³. Five patients on that dose, 1.5 percent, fell below 125 ¹³. All five were 65 or older, four were taking a glucocorticoid, a steroid medicine, and three a nonsteroidal anti-inflammatory painkiller ¹³.

Other effects follow the form. In the Nocdurna trials the common reactions were dry mouth, headache and dizziness ¹⁴. In the Noctiva trials they were nasal discomfort (5.9 percent against 4.9), nasopharyngitis (the common cold), nasal congestion, sneezing, raised blood pressure (2.6 against 1.1 percent) and nosebleeds ¹³. In the children's bedwetting trials the only drug-related reaction in 3 percent or more was headache, 4 percent against 3 on placebo ⁷. The Cochrane authors wrote that minor adverse effects were common, and their list includes dizziness, headache, mood changes, stomach and nasal discomfort, hyponatremia and one report of a convulsion ¹⁵.

The injection label's list of effects reported after marketing adds high and low blood pressure, fast heart rate, blood clots, fluid retention, nausea and abdominal cramps ¹. It also lists flushing, redness, swelling and burning pain, allergic (hypersensitivity) reactions and seizures from low sodium ¹. Its warnings cover a fall or rise in blood pressure, blood clots (thrombosis) in type IIB von Willebrand's disease, a different type from the approved type 1, and fluid retention ¹. They also cover hypersensitivity "including cases of fatal anaphylaxis with intravenous desmopressin acetate," anaphylaxis being a severe, sometimes fatal allergic reaction ¹.

The injection label says desmopressin must not be used in "hyponatremia or a history of hyponatremia," polydipsia (excessive drinking), and known or suspected SIADH, the syndrome of inappropriate antidiuretic hormone secretion ¹. It also bars it in moderate to severe kidney disease (renal impairment) and during illnesses that upset fluid or salt balance, such as gastroenteritis or systemic infection ¹. It bars it with loop diuretics, a class of water pills, and with systemic (whole-body) or inhaled glucocorticoids ¹. Heart failure and uncontrolled hypertension bar it too, because fluid retention can worsen them ¹.

Noctiva must not be used in primary nocturnal enuresis "because of reports of hyponatremic-related seizures in pediatric patients treated with other intranasal formulations" ¹³. The injection label says use in infants, children and older adults "will require careful fluid intake restriction to prevent possible hyponatremia and water intoxication" ¹. The oral solution contains benzoic acid, which its label calls a breakdown product (metabolite) of benzyl alcohol, and the label warns of benzyl alcohol toxicity in newborns ¹¹.

In sport

Desmopressin is named on the World Anti-Doping Agency's (WADA's) 2026 Prohibited List in section S5, "Diuretics and masking agents," a class prohibited at all times, in and out of competition ¹⁸. Masking agents are substances that can hide another drug in a test. The section reads "All diuretics and masking agents, including all optical isomers, e.g. d- and l- where relevant, are prohibited. Including, but not limited to:" ¹⁸. The bullets that follow name diuretics, vaptans, plasma expanders and, on a line of its own, "Desmopressin" ¹⁸.

What JumpstartMD offers

JumpstartMD does not prescribe desmopressin. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 10, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.